| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urologic Neoplasms | 63 | 2024 | 320 | 17.030 |
Why?
|
| Carcinoma, Transitional Cell | 89 | 2024 | 800 | 15.810 |
Why?
|
| Urinary Bladder Neoplasms | 135 | 2024 | 2275 | 14.830 |
Why?
|
| Urothelium | 36 | 2021 | 277 | 7.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 123 | 2024 | 11713 | 6.220 |
Why?
|
| Kidney Neoplasms | 70 | 2018 | 4312 | 5.420 |
Why?
|
| Carcinoma, Renal Cell | 65 | 2018 | 3218 | 5.400 |
Why?
|
| Antineoplastic Agents | 99 | 2021 | 13627 | 4.360 |
Why?
|
| Cisplatin | 46 | 2021 | 1643 | 3.980 |
Why?
|
| Vinblastine | 25 | 2019 | 487 | 3.570 |
Why?
|
| Taxoids | 29 | 2019 | 669 | 3.410 |
Why?
|
| Cystectomy | 32 | 2019 | 697 | 3.380 |
Why?
|
| Salvage Therapy | 16 | 2018 | 1268 | 2.640 |
Why?
|
| Antibodies, Monoclonal | 30 | 2024 | 9185 | 2.400 |
Why?
|
| Molecular Targeted Therapy | 19 | 2019 | 2803 | 2.330 |
Why?
|
| Deoxycytidine | 25 | 2019 | 872 | 2.330 |
Why?
|
| Carcinoma | 20 | 2018 | 2331 | 2.270 |
Why?
|
| Benzenesulfonates | 12 | 2010 | 165 | 2.190 |
Why?
|
| Pyrroles | 17 | 2014 | 1137 | 2.150 |
Why?
|
| Paclitaxel | 16 | 2024 | 1737 | 2.000 |
Why?
|
| Neoplasm Metastasis | 48 | 2019 | 4902 | 2.000 |
Why?
|
| Disease-Free Survival | 59 | 2021 | 6831 | 1.920 |
Why?
|
| Indoles | 17 | 2014 | 1829 | 1.890 |
Why?
|
| Nomograms | 6 | 2018 | 238 | 1.850 |
Why?
|
| Immunotherapy | 20 | 2021 | 4642 | 1.840 |
Why?
|
| Prostatic Neoplasms | 44 | 2019 | 11345 | 1.820 |
Why?
|
| Angiogenesis Inhibitors | 17 | 2017 | 2049 | 1.600 |
Why?
|
| Ureteral Neoplasms | 5 | 2016 | 110 | 1.540 |
Why?
|
| Survival Analysis | 55 | 2019 | 10185 | 1.540 |
Why?
|
| Pyridines | 15 | 2019 | 2879 | 1.500 |
Why?
|
| Organoplatinum Compounds | 7 | 2017 | 410 | 1.450 |
Why?
|
| Chemotherapy, Adjuvant | 28 | 2018 | 3530 | 1.390 |
Why?
|
| Urogenital Neoplasms | 4 | 2015 | 135 | 1.310 |
Why?
|
| Protein Kinase Inhibitors | 18 | 2016 | 5640 | 1.270 |
Why?
|
| Neoadjuvant Therapy | 22 | 2019 | 2821 | 1.160 |
Why?
|
| Endonucleases | 4 | 2017 | 370 | 1.160 |
Why?
|
| Humans | 399 | 2024 | 760613 | 1.150 |
Why?
|
| Prognosis | 62 | 2019 | 29661 | 1.140 |
Why?
|
| Neoplasm Invasiveness | 27 | 2021 | 3618 | 1.140 |
Why?
|
| Carboplatin | 17 | 2019 | 789 | 1.130 |
Why?
|
| Niacinamide | 16 | 2014 | 414 | 1.080 |
Why?
|
| Treatment Outcome | 114 | 2024 | 64981 | 1.070 |
Why?
|
| Imidazoles | 7 | 2019 | 1180 | 1.060 |
Why?
|
| Platinum | 7 | 2018 | 223 | 1.060 |
Why?
|
| Phenylthiohydantoin | 6 | 2016 | 204 | 1.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 14 | 2018 | 629 | 1.030 |
Why?
|
| Phenylurea Compounds | 16 | 2014 | 529 | 1.000 |
Why?
|
| Neoplasm Staging | 40 | 2018 | 11152 | 0.990 |
Why?
|
| TOR Serine-Threonine Kinases | 10 | 2024 | 2058 | 0.980 |
Why?
|
| Bone Neoplasms | 13 | 2018 | 2531 | 0.950 |
Why?
|
| Male | 236 | 2024 | 359718 | 0.940 |
Why?
|
| Muscles | 5 | 2021 | 1581 | 0.920 |
Why?
|
| Antineoplastic Agents, Hormonal | 9 | 2016 | 1529 | 0.900 |
Why?
|
| Aged | 168 | 2024 | 169143 | 0.900 |
Why?
|
| Orchiectomy | 9 | 2015 | 470 | 0.890 |
Why?
|
| Drug Administration Schedule | 26 | 2024 | 4899 | 0.870 |
Why?
|
| Prostate-Specific Antigen | 18 | 2019 | 2529 | 0.850 |
Why?
|
| Benzoxazoles | 2 | 2024 | 89 | 0.840 |
Why?
|
| Androgen Receptor Antagonists | 5 | 2016 | 123 | 0.830 |
Why?
|
| Neoplasm Recurrence, Local | 23 | 2020 | 9278 | 0.790 |
Why?
|
| Pyrimidines | 7 | 2024 | 3016 | 0.790 |
Why?
|
| Vascular Endothelial Growth Factor A | 12 | 2018 | 3484 | 0.780 |
Why?
|
| Androgen Antagonists | 15 | 2018 | 1442 | 0.770 |
Why?
|
| Sirolimus | 9 | 2014 | 1547 | 0.770 |
Why?
|
| Survival Rate | 31 | 2019 | 12810 | 0.770 |
Why?
|
| Gene Expression Regulation, Neoplastic | 14 | 2019 | 8512 | 0.760 |
Why?
|
| Middle Aged | 164 | 2024 | 220359 | 0.760 |
Why?
|
| Adenocarcinoma | 15 | 2018 | 6316 | 0.760 |
Why?
|
| Prostatectomy | 10 | 2017 | 1956 | 0.750 |
Why?
|
| Platinum Compounds | 6 | 2018 | 95 | 0.740 |
Why?
|
| Aged, 80 and over | 77 | 2024 | 58980 | 0.740 |
Why?
|
| Kaplan-Meier Estimate | 28 | 2018 | 6544 | 0.730 |
Why?
|
| Watchful Waiting | 5 | 2018 | 510 | 0.720 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2013 | 626 | 0.690 |
Why?
|
| Muscle Neoplasms | 4 | 2018 | 133 | 0.670 |
Why?
|
| Indazoles | 4 | 2018 | 302 | 0.670 |
Why?
|
| Female | 171 | 2024 | 391246 | 0.640 |
Why?
|
| Clinical Trials, Phase III as Topic | 15 | 2015 | 861 | 0.640 |
Why?
|
| Combined Modality Therapy | 22 | 2019 | 8552 | 0.620 |
Why?
|
| Urology | 4 | 2017 | 423 | 0.580 |
Why?
|
| Fluorouracil | 8 | 2014 | 1631 | 0.580 |
Why?
|
| Cancer Vaccines | 4 | 2014 | 1046 | 0.570 |
Why?
|
| Radium | 3 | 2018 | 72 | 0.570 |
Why?
|
| DNA Copy Number Variations | 6 | 2018 | 2013 | 0.560 |
Why?
|
| Radiotherapy | 7 | 2017 | 1504 | 0.560 |
Why?
|
| Morpholines | 2 | 2019 | 583 | 0.550 |
Why?
|
| Cytosine Deaminase | 1 | 2016 | 65 | 0.530 |
Why?
|
| Societies, Medical | 8 | 2019 | 3905 | 0.520 |
Why?
|
| Mutation | 21 | 2024 | 29957 | 0.520 |
Why?
|
| Gene Dosage | 3 | 2020 | 1218 | 0.520 |
Why?
|
| Radiopharmaceuticals | 4 | 2014 | 2634 | 0.510 |
Why?
|
| Health Planning Guidelines | 3 | 2014 | 151 | 0.510 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2015 | 97 | 0.510 |
Why?
|
| Methotrexate | 18 | 2015 | 1718 | 0.510 |
Why?
|
| Neovascularization, Pathologic | 7 | 2016 | 2640 | 0.500 |
Why?
|
| Clinical Trials as Topic | 24 | 2018 | 8055 | 0.500 |
Why?
|
| BCG Vaccine | 4 | 2018 | 371 | 0.500 |
Why?
|
| Prednisone | 7 | 2017 | 1566 | 0.500 |
Why?
|
| Perioperative Care | 4 | 2015 | 1037 | 0.500 |
Why?
|
| Follow-Up Studies | 32 | 2020 | 39262 | 0.490 |
Why?
|
| Infusions, Intravenous | 9 | 2017 | 2235 | 0.480 |
Why?
|
| Drug Resistance, Neoplasm | 17 | 2017 | 5251 | 0.480 |
Why?
|
| DNA-Binding Proteins | 6 | 2019 | 9591 | 0.480 |
Why?
|
| Randomized Controlled Trials as Topic | 21 | 2019 | 10343 | 0.480 |
Why?
|
| Disease Progression | 25 | 2018 | 13505 | 0.470 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 3 | 2020 | 104 | 0.460 |
Why?
|
| Anilides | 3 | 2015 | 409 | 0.450 |
Why?
|
| Carcinoma in Situ | 3 | 2017 | 796 | 0.450 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2019 | 10826 | 0.430 |
Why?
|
| Kallikreins | 3 | 2016 | 231 | 0.430 |
Why?
|
| Adult | 95 | 2024 | 220007 | 0.430 |
Why?
|
| Alpha Particles | 1 | 2012 | 29 | 0.420 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2016 | 1613 | 0.420 |
Why?
|
| Spain | 9 | 2015 | 488 | 0.420 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2017 | 1088 | 0.420 |
Why?
|
| Patient-Centered Care | 3 | 2012 | 1416 | 0.410 |
Why?
|
| Gene Expression Profiling | 8 | 2018 | 9406 | 0.410 |
Why?
|
| Interferon-alpha | 9 | 2013 | 919 | 0.410 |
Why?
|
| Lymph Node Excision | 8 | 2017 | 1303 | 0.410 |
Why?
|
| Serum Albumin | 1 | 2015 | 674 | 0.400 |
Why?
|
| Gonadotropin-Releasing Hormone | 4 | 2018 | 1153 | 0.400 |
Why?
|
| Drugs, Investigational | 2 | 2011 | 214 | 0.390 |
Why?
|
| Sulfonamides | 3 | 2018 | 1977 | 0.390 |
Why?
|
| Fluorine Radioisotopes | 1 | 2014 | 413 | 0.390 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2018 | 3617 | 0.380 |
Why?
|
| Receptor, erbB-2 | 4 | 2016 | 2554 | 0.370 |
Why?
|
| Hyponatremia | 1 | 2013 | 279 | 0.370 |
Why?
|
| Designer Drugs | 1 | 2010 | 21 | 0.370 |
Why?
|
| Ifosfamide | 3 | 1998 | 232 | 0.370 |
Why?
|
| Muscle, Smooth | 5 | 2017 | 924 | 0.360 |
Why?
|
| Urinary Bladder | 6 | 2018 | 1166 | 0.350 |
Why?
|
| Proportional Hazards Models | 18 | 2017 | 12531 | 0.350 |
Why?
|
| Benzamides | 7 | 2018 | 1369 | 0.350 |
Why?
|
| Doxorubicin | 11 | 2015 | 2208 | 0.350 |
Why?
|
| Maximum Tolerated Dose | 5 | 2017 | 877 | 0.350 |
Why?
|
| Genomics | 6 | 2018 | 5795 | 0.350 |
Why?
|
| Europe | 12 | 2017 | 3441 | 0.350 |
Why?
|
| Quality of Life | 12 | 2018 | 13308 | 0.340 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2014 | 628 | 0.340 |
Why?
|
| Practice Guidelines as Topic | 11 | 2018 | 7475 | 0.340 |
Why?
|
| Rectum | 1 | 2014 | 895 | 0.340 |
Why?
|
| Carbon Radioisotopes | 1 | 2010 | 557 | 0.330 |
Why?
|
| Lymphatic Metastasis | 11 | 2017 | 2943 | 0.330 |
Why?
|
| Immunotherapy, Active | 1 | 2009 | 59 | 0.320 |
Why?
|
| Hemoglobins | 2 | 2017 | 1521 | 0.320 |
Why?
|
| Liver Neoplasms | 10 | 2017 | 4319 | 0.320 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2014 | 2007 | 0.310 |
Why?
|
| Nitriles | 8 | 2016 | 956 | 0.310 |
Why?
|
| Drug Carriers | 1 | 2013 | 709 | 0.310 |
Why?
|
| Sodium | 1 | 2013 | 1594 | 0.310 |
Why?
|
| Methionine | 1 | 2010 | 569 | 0.300 |
Why?
|
| Retrospective Studies | 38 | 2019 | 80345 | 0.300 |
Why?
|
| HSP27 Heat-Shock Proteins | 2 | 2018 | 67 | 0.300 |
Why?
|
| Interleukin-8 | 1 | 2011 | 698 | 0.300 |
Why?
|
| Neutropenia | 5 | 2017 | 884 | 0.300 |
Why?
|
| Tubulin Modulators | 1 | 2008 | 107 | 0.300 |
Why?
|
| Sarcoma | 4 | 2011 | 1786 | 0.300 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2010 | 1152 | 0.300 |
Why?
|
| Tetrahydroisoquinolines | 3 | 2014 | 81 | 0.300 |
Why?
|
| Stomach Neoplasms | 4 | 2012 | 1424 | 0.290 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 4 | 2013 | 666 | 0.290 |
Why?
|
| Predictive Value of Tests | 13 | 2018 | 15286 | 0.290 |
Why?
|
| Thromboembolism | 2 | 2012 | 1016 | 0.280 |
Why?
|
| Positron-Emission Tomography | 3 | 2014 | 6465 | 0.280 |
Why?
|
| Administration, Oral | 9 | 2019 | 4035 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 2448 | 0.270 |
Why?
|
| Palliative Care | 5 | 2012 | 3607 | 0.270 |
Why?
|
| Colon | 1 | 2014 | 1788 | 0.270 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2020 | 698 | 0.270 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2018 | 104 | 0.270 |
Why?
|
| Drug Delivery Systems | 2 | 2016 | 2221 | 0.260 |
Why?
|
| MicroRNAs | 4 | 2017 | 3787 | 0.260 |
Why?
|
| Prospective Studies | 21 | 2018 | 54306 | 0.260 |
Why?
|
| Nephrectomy | 8 | 2017 | 1016 | 0.260 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2010 | 752 | 0.260 |
Why?
|
| Patient Selection | 9 | 2019 | 4279 | 0.260 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 2864 | 0.260 |
Why?
|
| Medical Oncology | 4 | 2018 | 2313 | 0.250 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2009 | 640 | 0.250 |
Why?
|
| Biological Products | 1 | 2014 | 916 | 0.250 |
Why?
|
| Neoplasm Proteins | 3 | 2015 | 3612 | 0.250 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2011 | 618 | 0.240 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2005 | 86 | 0.240 |
Why?
|
| Colorectal Neoplasms | 7 | 2016 | 6853 | 0.240 |
Why?
|
| Nails | 3 | 1991 | 295 | 0.230 |
Why?
|
| Time Factors | 27 | 2018 | 40139 | 0.230 |
Why?
|
| Lung Neoplasms | 14 | 2015 | 13262 | 0.230 |
Why?
|
| DNA Repair | 3 | 2018 | 2038 | 0.220 |
Why?
|
| Protective Agents | 2 | 2014 | 150 | 0.220 |
Why?
|
| Administration, Intravesical | 3 | 2018 | 92 | 0.220 |
Why?
|
| Double-Blind Method | 11 | 2017 | 12427 | 0.210 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2018 | 1347 | 0.210 |
Why?
|
| Molecular Chaperones | 3 | 2018 | 752 | 0.210 |
Why?
|
| Treatment Failure | 5 | 2013 | 2647 | 0.210 |
Why?
|
| Signal Transduction | 8 | 2016 | 23374 | 0.210 |
Why?
|
| Risk Assessment | 14 | 2018 | 24102 | 0.210 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2014 | 473 | 0.210 |
Why?
|
| Thalidomide | 3 | 2017 | 884 | 0.200 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 1173 | 0.200 |
Why?
|
| Tegafur | 3 | 1998 | 39 | 0.200 |
Why?
|
| Bone Remodeling | 3 | 2018 | 580 | 0.200 |
Why?
|
| Drug Synergism | 3 | 2019 | 1752 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2019 | 3583 | 0.190 |
Why?
|
| Nanoparticles | 1 | 2013 | 1943 | 0.190 |
Why?
|
| Immunosuppressive Agents | 2 | 2012 | 4167 | 0.190 |
Why?
|
| Adjuvants, Immunologic | 1 | 2007 | 1039 | 0.190 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2024 | 376 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2020 | 2924 | 0.190 |
Why?
|
| Leucovorin | 4 | 1998 | 641 | 0.190 |
Why?
|
| Italy | 2 | 2013 | 841 | 0.190 |
Why?
|
| Cell Line, Tumor | 9 | 2019 | 16932 | 0.190 |
Why?
|
| Risk Factors | 22 | 2018 | 74333 | 0.190 |
Why?
|
| Colonic Neoplasms | 1 | 2013 | 2526 | 0.190 |
Why?
|
| RNA, Messenger | 7 | 2016 | 12762 | 0.180 |
Why?
|
| Urinary Diversion | 2 | 2018 | 135 | 0.180 |
Why?
|
| Dioxoles | 2 | 2011 | 95 | 0.180 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2015 | 2505 | 0.180 |
Why?
|
| Brachytherapy | 3 | 2017 | 1238 | 0.180 |
Why?
|
| Alkaline Phosphatase | 2 | 2013 | 865 | 0.180 |
Why?
|
| Bleomycin | 3 | 1991 | 495 | 0.180 |
Why?
|
| Vinca Alkaloids | 2 | 2011 | 36 | 0.180 |
Why?
|
| Cholangiocarcinoma | 1 | 2006 | 548 | 0.180 |
Why?
|
| Drug Therapy | 2 | 2014 | 504 | 0.180 |
Why?
|
| Breast Neoplasms | 16 | 2011 | 21029 | 0.180 |
Why?
|
| Cohort Studies | 16 | 2018 | 41337 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2014 | 4024 | 0.170 |
Why?
|
| Cyclin E | 1 | 2020 | 155 | 0.170 |
Why?
|
| Lymph Nodes | 5 | 2017 | 3486 | 0.170 |
Why?
|
| Patient Care Team | 2 | 2008 | 2511 | 0.170 |
Why?
|
| Animals | 19 | 2019 | 167960 | 0.160 |
Why?
|
| Hemangioendothelioma | 2 | 1990 | 111 | 0.160 |
Why?
|
| Genetic Variation | 1 | 2014 | 6552 | 0.160 |
Why?
|
| Breast Neoplasms, Male | 2 | 1998 | 221 | 0.160 |
Why?
|
| Benzodiazepines | 1 | 2005 | 1131 | 0.160 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2019 | 165 | 0.160 |
Why?
|
| Membrane Proteins | 1 | 2015 | 7850 | 0.160 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 2 | 2016 | 40 | 0.160 |
Why?
|
| CREB-Binding Protein | 1 | 2018 | 148 | 0.160 |
Why?
|
| Adenine | 1 | 2024 | 975 | 0.160 |
Why?
|
| Bronchial Neoplasms | 2 | 1996 | 110 | 0.160 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2018 | 123 | 0.150 |
Why?
|
| Diphosphonates | 2 | 2013 | 638 | 0.150 |
Why?
|
| Radioisotopes | 3 | 2018 | 495 | 0.150 |
Why?
|
| Venous Thromboembolism | 3 | 2016 | 1864 | 0.150 |
Why?
|
| Chromosome Aberrations | 2 | 2015 | 1767 | 0.150 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2012 | 1791 | 0.150 |
Why?
|
| Androstenes | 3 | 2014 | 182 | 0.150 |
Why?
|
| Asthenia | 1 | 2017 | 16 | 0.150 |
Why?
|
| Disease Management | 4 | 2017 | 2514 | 0.150 |
Why?
|
| Antidotes | 1 | 1998 | 138 | 0.140 |
Why?
|
| Gene Deletion | 2 | 2015 | 2668 | 0.140 |
Why?
|
| Heat-Shock Proteins | 2 | 2018 | 795 | 0.140 |
Why?
|
| Congresses as Topic | 2 | 2012 | 805 | 0.140 |
Why?
|
| Cyclin D1 | 1 | 1998 | 451 | 0.140 |
Why?
|
| Galectins | 1 | 2019 | 282 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 2 | 2011 | 5349 | 0.140 |
Why?
|
| Random Allocation | 2 | 2018 | 2394 | 0.130 |
Why?
|
| Cryosurgery | 3 | 2016 | 475 | 0.130 |
Why?
|
| Oncogene Proteins | 1 | 2020 | 719 | 0.130 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2012 | 326 | 0.130 |
Why?
|
| Neoplasms | 11 | 2018 | 22075 | 0.130 |
Why?
|
| Microsatellite Repeats | 1 | 2018 | 786 | 0.130 |
Why?
|
| Rosa | 1 | 2015 | 8 | 0.130 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 422 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 2 | 2013 | 119 | 0.130 |
Why?
|
| Endpoint Determination | 1 | 2018 | 597 | 0.130 |
Why?
|
| E2F3 Transcription Factor | 1 | 2015 | 36 | 0.130 |
Why?
|
| BRCA1 Protein | 2 | 2015 | 1147 | 0.120 |
Why?
|
| Androstenols | 2 | 2013 | 25 | 0.120 |
Why?
|
| Histone Code | 1 | 2016 | 156 | 0.120 |
Why?
|
| Immunohistochemistry | 5 | 2015 | 11070 | 0.120 |
Why?
|
| Rad51 Recombinase | 1 | 2015 | 188 | 0.120 |
Why?
|
| Kidney Pelvis | 1 | 2016 | 188 | 0.120 |
Why?
|
| Oligonucleotides | 1 | 2018 | 588 | 0.120 |
Why?
|
| Internationality | 2 | 2017 | 1004 | 0.120 |
Why?
|
| Adenoma, Villous | 1 | 2014 | 14 | 0.120 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2017 | 459 | 0.120 |
Why?
|
| Blood Cell Count | 1 | 2015 | 398 | 0.120 |
Why?
|
| Cytidine Deaminase | 1 | 2016 | 245 | 0.120 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1996 | 590 | 0.120 |
Why?
|
| Genes, erbB-1 | 1 | 2015 | 160 | 0.120 |
Why?
|
| Cluster Analysis | 3 | 2017 | 2698 | 0.110 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 12159 | 0.110 |
Why?
|
| Retreatment | 1 | 2015 | 600 | 0.110 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1994 | 79 | 0.110 |
Why?
|
| Recombinant Proteins | 7 | 2014 | 6538 | 0.110 |
Why?
|
| Single-Blind Method | 1 | 2017 | 1578 | 0.110 |
Why?
|
| Androstadienes | 2 | 2013 | 348 | 0.110 |
Why?
|
| Cystoscopy | 2 | 2012 | 133 | 0.110 |
Why?
|
| Geriatrics | 1 | 2018 | 387 | 0.110 |
Why?
|
| Standard of Care | 1 | 2017 | 552 | 0.110 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2014 | 87 | 0.110 |
Why?
|
| Immunomodulation | 1 | 2017 | 547 | 0.110 |
Why?
|
| Remission Induction | 5 | 2010 | 2392 | 0.110 |
Why?
|
| Mutation, Missense | 3 | 2018 | 2567 | 0.110 |
Why?
|
| Receptors, Androgen | 2 | 2018 | 1077 | 0.110 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 1078 | 0.110 |
Why?
|
| Estrogen Antagonists | 2 | 2008 | 151 | 0.110 |
Why?
|
| Wilms Tumor | 2 | 1994 | 375 | 0.110 |
Why?
|
| Achievement | 1 | 2014 | 289 | 0.110 |
Why?
|
| Cyclophosphamide | 7 | 2000 | 2222 | 0.110 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 1992 | 169 | 0.110 |
Why?
|
| Biopsy | 6 | 2017 | 6771 | 0.110 |
Why?
|
| Capillaries | 3 | 1991 | 744 | 0.100 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2014 | 160 | 0.100 |
Why?
|
| Incidence | 6 | 2016 | 21391 | 0.100 |
Why?
|
| Carcinoma, Small Cell | 3 | 2008 | 416 | 0.100 |
Why?
|
| Leiomyoma | 1 | 1997 | 654 | 0.100 |
Why?
|
| Constipation | 1 | 2017 | 561 | 0.100 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 1993 | 748 | 0.100 |
Why?
|
| HIV Seropositivity | 2 | 1995 | 955 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 3332 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2016 | 2802 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 1705 | 0.100 |
Why?
|
| Neoplasms, Second Primary | 2 | 2017 | 1060 | 0.100 |
Why?
|
| Seminoma | 1 | 2012 | 134 | 0.100 |
Why?
|
| Urinary Tract | 1 | 2014 | 309 | 0.090 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2011 | 99 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2016 | 727 | 0.090 |
Why?
|
| BRCA2 Protein | 1 | 2015 | 798 | 0.090 |
Why?
|
| Expert Testimony | 1 | 2013 | 361 | 0.090 |
Why?
|
| Microscopy | 3 | 1991 | 885 | 0.090 |
Why?
|
| Gene Frequency | 2 | 2015 | 3613 | 0.090 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2010 | 42 | 0.090 |
Why?
|
| Raynaud Disease | 1 | 1991 | 79 | 0.090 |
Why?
|
| Gene Amplification | 1 | 2015 | 1085 | 0.090 |
Why?
|
| Albumins | 1 | 2013 | 577 | 0.090 |
Why?
|
| DNA Damage | 2 | 2018 | 2442 | 0.090 |
Why?
|
| Comparative Effectiveness Research | 2 | 2017 | 718 | 0.090 |
Why?
|
| Geriatric Assessment | 3 | 2018 | 1405 | 0.090 |
Why?
|
| Mediastinal Neoplasms | 2 | 2012 | 402 | 0.090 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 361 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 2 | 2018 | 4716 | 0.090 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 730 | 0.090 |
Why?
|
| Drug Approval | 1 | 2017 | 816 | 0.090 |
Why?
|
| Cell Survival | 2 | 2019 | 5797 | 0.090 |
Why?
|
| Tumor Burden | 2 | 2013 | 1895 | 0.090 |
Why?
|
| Hemorrhage | 2 | 2012 | 3599 | 0.090 |
Why?
|
| Lymphocytes | 1 | 2018 | 2611 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 8985 | 0.090 |
Why?
|
| Mitoxantrone | 1 | 1990 | 149 | 0.090 |
Why?
|
| Fatigue | 1 | 2017 | 1544 | 0.090 |
Why?
|
| Logistic Models | 6 | 2018 | 13312 | 0.080 |
Why?
|
| Linear Models | 2 | 2010 | 5877 | 0.080 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2016 | 938 | 0.080 |
Why?
|
| Receptors, Growth Factor | 1 | 2010 | 326 | 0.080 |
Why?
|
| Colonic Polyps | 1 | 2014 | 551 | 0.080 |
Why?
|
| Half-Life | 1 | 2010 | 652 | 0.080 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 1356 | 0.080 |
Why?
|
| Consensus | 3 | 2019 | 3113 | 0.080 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2012 | 329 | 0.080 |
Why?
|
| Evidence-Based Medicine | 8 | 2014 | 3696 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 558 | 0.080 |
Why?
|
| Propensity Score | 4 | 2018 | 1926 | 0.080 |
Why?
|
| Observer Variation | 1 | 2015 | 2601 | 0.080 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 1677 | 0.080 |
Why?
|
| Uterine Neoplasms | 1 | 1997 | 1439 | 0.080 |
Why?
|
| Thrombocytopenia | 2 | 2012 | 1174 | 0.080 |
Why?
|
| Recurrence | 2 | 2018 | 8483 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2019 | 2982 | 0.080 |
Why?
|
| Tissue Distribution | 1 | 2012 | 2262 | 0.080 |
Why?
|
| Codon | 1 | 2010 | 602 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2010 | 2418 | 0.080 |
Why?
|
| Enzyme Inhibitors | 3 | 2011 | 3725 | 0.070 |
Why?
|
| Precancerous Conditions | 1 | 2014 | 977 | 0.070 |
Why?
|
| Databases, Factual | 6 | 2018 | 8022 | 0.070 |
Why?
|
| Progestins | 1 | 2009 | 302 | 0.070 |
Why?
|
| Odds Ratio | 4 | 2017 | 9716 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2009 | 748 | 0.070 |
Why?
|
| Paresthesia | 1 | 1988 | 162 | 0.070 |
Why?
|
| Cell Line | 3 | 2018 | 15620 | 0.070 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2007 | 32 | 0.070 |
Why?
|
| Epigenesis, Genetic | 2 | 2017 | 3759 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 1998 | 3448 | 0.070 |
Why?
|
| Estrogen Receptor beta | 1 | 2008 | 168 | 0.070 |
Why?
|
| HEK293 Cells | 1 | 2016 | 4263 | 0.070 |
Why?
|
| Erythema | 1 | 1988 | 262 | 0.070 |
Why?
|
| S Phase | 1 | 2008 | 422 | 0.070 |
Why?
|
| DNA Methylation | 2 | 2017 | 4372 | 0.070 |
Why?
|
| G1 Phase | 1 | 2008 | 403 | 0.070 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2011 | 611 | 0.070 |
Why?
|
| Colonoscopy | 1 | 2014 | 1387 | 0.070 |
Why?
|
| Stress, Physiological | 1 | 2014 | 1398 | 0.070 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2008 | 307 | 0.070 |
Why?
|
| Tamoxifen | 1 | 1991 | 963 | 0.070 |
Why?
|
| Interleukin-2 | 2 | 2009 | 1889 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2014 | 1869 | 0.070 |
Why?
|
| Drug Discovery | 1 | 2014 | 1057 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 6498 | 0.060 |
Why?
|
| Heart Neoplasms | 1 | 1989 | 360 | 0.060 |
Why?
|
| Mice | 5 | 2019 | 81209 | 0.060 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 1343 | 0.060 |
Why?
|
| Postoperative Complications | 3 | 2017 | 15679 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2010 | 1493 | 0.060 |
Why?
|
| Genetic Loci | 1 | 2015 | 2618 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2019 | 10442 | 0.060 |
Why?
|
| Phenotype | 4 | 2016 | 16548 | 0.060 |
Why?
|
| Growth Substances | 2 | 1998 | 768 | 0.060 |
Why?
|
| Hematologic Diseases | 1 | 2009 | 497 | 0.060 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2017 | 2782 | 0.060 |
Why?
|
| Farnesyltranstransferase | 1 | 2005 | 71 | 0.060 |
Why?
|
| Caveolin 1 | 1 | 2007 | 257 | 0.060 |
Why?
|
| Aging | 2 | 2018 | 8652 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 1376 | 0.060 |
Why?
|
| Neutrophils | 1 | 2018 | 3767 | 0.060 |
Why?
|
| Health Status | 1 | 2018 | 4082 | 0.060 |
Why?
|
| Databases as Topic | 1 | 2007 | 474 | 0.060 |
Why?
|
| Tissue Extracts | 2 | 2016 | 140 | 0.060 |
Why?
|
| Risk | 3 | 2013 | 9632 | 0.060 |
Why?
|
| United States | 6 | 2018 | 72448 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2016 | 36286 | 0.060 |
Why?
|
| DNA Mutational Analysis | 3 | 2018 | 4108 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 5795 | 0.060 |
Why?
|
| Comorbidity | 2 | 2011 | 10553 | 0.060 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2010 | 615 | 0.060 |
Why?
|
| Esophageal Neoplasms | 2 | 2011 | 1648 | 0.060 |
Why?
|
| Diarrhea | 2 | 2009 | 1319 | 0.060 |
Why?
|
| CpG Islands | 1 | 2008 | 1221 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 2829 | 0.050 |
Why?
|
| Age Factors | 5 | 2018 | 18413 | 0.050 |
Why?
|
| Adolescent | 7 | 2021 | 87809 | 0.050 |
Why?
|
| Young Adult | 8 | 2018 | 58748 | 0.050 |
Why?
|
| Naphthalenes | 2 | 2015 | 198 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2013 | 3442 | 0.050 |
Why?
|
| Pleural Neoplasms | 1 | 2008 | 609 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2010 | 1927 | 0.050 |
Why?
|
| Microfilament Proteins | 1 | 2008 | 1135 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2008 | 752 | 0.050 |
Why?
|
| Survival | 2 | 2013 | 161 | 0.050 |
Why?
|
| Pelvis | 2 | 2017 | 743 | 0.050 |
Why?
|
| Computational Biology | 1 | 2015 | 3505 | 0.050 |
Why?
|
| Early Detection of Cancer | 2 | 2016 | 3202 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 2896 | 0.050 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 3386 | 0.050 |
Why?
|
| Leukocyte Count | 2 | 2016 | 1599 | 0.050 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2011 | 412 | 0.050 |
Why?
|
| Quinolones | 2 | 2017 | 377 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2006 | 680 | 0.050 |
Why?
|
| Bone Density Conservation Agents | 3 | 2014 | 796 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2011 | 20509 | 0.050 |
Why?
|
| Mesothelioma | 1 | 2008 | 807 | 0.050 |
Why?
|
| Tosyl Compounds | 1 | 2002 | 112 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2009 | 1612 | 0.050 |
Why?
|
| Flutamide | 1 | 2002 | 95 | 0.050 |
Why?
|
| Safety | 2 | 2017 | 1148 | 0.050 |
Why?
|
| Laparoscopy | 1 | 2014 | 2147 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2008 | 1754 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2014 | 635 | 0.050 |
Why?
|
| Skin Diseases | 1 | 2010 | 1089 | 0.050 |
Why?
|
| Down-Regulation | 2 | 2019 | 2913 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 1990 | 1181 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2012 | 2093 | 0.050 |
Why?
|
| Diagnostic Imaging | 2 | 2014 | 3527 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2016 | 3426 | 0.050 |
Why?
|
| Kinetics | 1 | 2009 | 6377 | 0.050 |
Why?
|
| North America | 2 | 2015 | 1284 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2018 | 2897 | 0.050 |
Why?
|
| Receptors, Virus | 1 | 2004 | 639 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2009 | 3157 | 0.040 |
Why?
|
| Algorithms | 3 | 2012 | 13982 | 0.040 |
Why?
|
| Drug Evaluation | 2 | 1992 | 641 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2006 | 820 | 0.040 |
Why?
|
| History, 21st Century | 2 | 2017 | 1575 | 0.040 |
Why?
|
| DNA | 1 | 2013 | 7233 | 0.040 |
Why?
|
| Actuarial Analysis | 2 | 1996 | 374 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2019 | 12102 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2017 | 1137 | 0.040 |
Why?
|
| Registries | 1 | 2015 | 8458 | 0.040 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 3709 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2016 | 17790 | 0.040 |
Why?
|
| Cardiovascular Diseases | 4 | 2016 | 15760 | 0.040 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 2018 | 29 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2001 | 5201 | 0.040 |
Why?
|
| ras Proteins | 2 | 2016 | 1051 | 0.040 |
Why?
|
| Megestrol Acetate | 1 | 1998 | 18 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2007 | 6238 | 0.040 |
Why?
|
| Smoking | 1 | 2015 | 9073 | 0.040 |
Why?
|
| Models, Biological | 2 | 2014 | 9468 | 0.040 |
Why?
|
| Contrast Media | 1 | 2011 | 5305 | 0.040 |
Why?
|
| Orbital Neoplasms | 2 | 1991 | 221 | 0.040 |
Why?
|
| Forecasting | 1 | 2006 | 2931 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1990 | 2299 | 0.040 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2017 | 38 | 0.040 |
Why?
|
| International Agencies | 1 | 2017 | 244 | 0.040 |
Why?
|
| Reproducibility of Results | 4 | 2017 | 20080 | 0.040 |
Why?
|
| Retroperitoneal Space | 1 | 2017 | 173 | 0.030 |
Why?
|
| Quinazolines | 2 | 2014 | 1363 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 1996 | 165 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 2 | 2011 | 1189 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 1994 | 1378 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2002 | 708 | 0.030 |
Why?
|
| DNA, Neoplasm | 2 | 2016 | 1745 | 0.030 |
Why?
|
| Kidney | 1 | 2011 | 7064 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2001 | 2025 | 0.030 |
Why?
|
| Uracil | 1 | 1997 | 207 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2015 | 6359 | 0.030 |
Why?
|
| Radiography | 3 | 2015 | 6965 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 302 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2016 | 241 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1998 | 886 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2019 | 704 | 0.030 |
Why?
|
| Ureteroscopy | 1 | 2016 | 148 | 0.030 |
Why?
|
| Mass Screening | 1 | 2010 | 5422 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2016 | 358 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2019 | 1516 | 0.030 |
Why?
|
| Filgrastim | 1 | 2014 | 132 | 0.030 |
Why?
|
| Direct Service Costs | 1 | 2014 | 60 | 0.030 |
Why?
|
| Gene Expression | 3 | 2014 | 7587 | 0.030 |
Why?
|
| Cell Movement | 2 | 2013 | 5206 | 0.030 |
Why?
|
| Aromatase Inhibitors | 1 | 1998 | 511 | 0.030 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2014 | 59 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 1837 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2016 | 2053 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2018 | 772 | 0.030 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 413 | 0.030 |
Why?
|
| Thionucleotides | 1 | 2013 | 112 | 0.030 |
Why?
|
| Mitomycin | 2 | 1991 | 262 | 0.030 |
Why?
|
| Carcinoma, Large Cell | 1 | 1994 | 113 | 0.030 |
Why?
|
| Ureter | 1 | 2016 | 375 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 858 | 0.030 |
Why?
|
| Point Mutation | 1 | 1998 | 1594 | 0.030 |
Why?
|
| Child | 3 | 2017 | 79799 | 0.030 |
Why?
|
| Urologic Surgical Procedures | 1 | 2016 | 309 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2016 | 603 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 2627 | 0.030 |
Why?
|
| Extracellular Space | 1 | 2015 | 564 | 0.030 |
Why?
|
| Procollagen | 1 | 2013 | 188 | 0.030 |
Why?
|
| Choroid Neoplasms | 1 | 1994 | 177 | 0.030 |
Why?
|
| Triazoles | 1 | 1998 | 904 | 0.030 |
Why?
|
| Immunity | 1 | 2018 | 998 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2016 | 565 | 0.030 |
Why?
|
| Paracrine Communication | 1 | 2014 | 277 | 0.030 |
Why?
|
| Anemia | 1 | 2002 | 1511 | 0.030 |
Why?
|
| Publication Bias | 1 | 2013 | 162 | 0.030 |
Why?
|
| Expert Systems | 1 | 2012 | 79 | 0.030 |
Why?
|
| Length of Stay | 2 | 2017 | 6476 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 15790 | 0.020 |
Why?
|
| Asia | 1 | 2013 | 620 | 0.020 |
Why?
|
| Polyarteritis Nodosa | 1 | 1992 | 70 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2011 | 114 | 0.020 |
Why?
|
| Papilloma | 1 | 1992 | 141 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2016 | 664 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2014 | 657 | 0.020 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1995 | 533 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 657 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2013 | 535 | 0.020 |
Why?
|
| Addison Disease | 1 | 1990 | 48 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 632 | 0.020 |
Why?
|
| Placebos | 1 | 2015 | 1668 | 0.020 |
Why?
|
| Spinal Cord Compression | 1 | 1992 | 235 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2017 | 1247 | 0.020 |
Why?
|
| Prostate | 1 | 2018 | 1793 | 0.020 |
Why?
|
| Laryngeal Neoplasms | 1 | 1994 | 514 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2012 | 956 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2015 | 1722 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2013 | 616 | 0.020 |
Why?
|
| Hypertension | 1 | 2010 | 8595 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 1996 | 1296 | 0.020 |
Why?
|
| Tonsillar Neoplasms | 1 | 1990 | 50 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 5251 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 1994 | 1229 | 0.020 |
Why?
|
| Mitomycins | 1 | 1989 | 46 | 0.020 |
Why?
|
| RANK Ligand | 1 | 2011 | 318 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2015 | 1677 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2013 | 877 | 0.020 |
Why?
|
| Estrogens | 1 | 2015 | 1520 | 0.020 |
Why?
|
| Apoptosis | 1 | 2005 | 9497 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 1997 | 1231 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 1189 | 0.020 |
Why?
|
| Genetic Markers | 1 | 1994 | 2609 | 0.020 |
Why?
|
| Thrombophlebitis | 1 | 1989 | 289 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 2005 | 0.020 |
Why?
|
| Rectal Neoplasms | 1 | 1997 | 1152 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2018 | 2688 | 0.020 |
Why?
|
| Interferons | 1 | 1991 | 705 | 0.020 |
Why?
|
| Quinolines | 1 | 2013 | 759 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2014 | 976 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 1991 | 1490 | 0.020 |
Why?
|
| Salmonella Infections | 1 | 1989 | 171 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2015 | 2773 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 1997 | 2063 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 5039 | 0.020 |
Why?
|
| Patient Preference | 1 | 2014 | 922 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2008 | 6065 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 1788 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2013 | 1512 | 0.020 |
Why?
|
| Magnesium | 1 | 1990 | 810 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 551 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1997 | 2914 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 1994 | 1380 | 0.020 |
Why?
|
| Heart Failure | 1 | 2011 | 11848 | 0.020 |
Why?
|
| Thiazoles | 1 | 2013 | 1511 | 0.020 |
Why?
|
| Acromegaly | 1 | 1989 | 306 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 1995 | 2145 | 0.020 |
Why?
|
| Piperidines | 1 | 2014 | 1650 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 1992 | 978 | 0.020 |
Why?
|
| Interferon Type I | 1 | 1990 | 559 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2008 | 492 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1990 | 586 | 0.020 |
Why?
|
| Methylation | 1 | 2008 | 1081 | 0.020 |
Why?
|
| Spinal Neoplasms | 1 | 1992 | 716 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 1 | 1994 | 916 | 0.020 |
Why?
|
| Epitopes | 1 | 2012 | 2503 | 0.020 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1990 | 733 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2007 | 681 | 0.020 |
Why?
|
| Lymphoma | 1 | 1994 | 1899 | 0.020 |
Why?
|
| Heterozygote | 1 | 2011 | 2798 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2015 | 3527 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2009 | 632 | 0.010 |
Why?
|
| Cell Division | 2 | 2004 | 4463 | 0.010 |
Why?
|
| Hepatitis A virus | 1 | 2004 | 16 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2008 | 1693 | 0.010 |
Why?
|
| Reoperation | 1 | 2014 | 4289 | 0.010 |
Why?
|
| Transgenes | 1 | 2008 | 1006 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2015 | 5869 | 0.010 |
Why?
|
| Foot | 1 | 1988 | 573 | 0.010 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 934 | 0.010 |
Why?
|
| ROC Curve | 1 | 2011 | 3568 | 0.010 |
Why?
|
| Androgens | 1 | 2011 | 1291 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2001 | 15840 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2015 | 2064 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2017 | 3322 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2018 | 14374 | 0.010 |
Why?
|
| Hand | 1 | 1988 | 903 | 0.010 |
Why?
|
| Cerebellar Neoplasms | 1 | 1988 | 586 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2004 | 385 | 0.010 |
Why?
|
| Menopause | 1 | 1991 | 1640 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2013 | 2560 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1990 | 1266 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2010 | 1728 | 0.010 |
Why?
|
| Syndrome | 1 | 1988 | 3280 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2004 | 748 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2013 | 5132 | 0.010 |
Why?
|
| Estradiol | 1 | 2008 | 1932 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1993 | 4938 | 0.010 |
Why?
|
| Vaccination | 1 | 2011 | 3359 | 0.010 |
Why?
|
| Binding Sites | 1 | 2008 | 6048 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 1992 | 2332 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2016 | 22052 | 0.010 |
Why?
|
| Rats | 1 | 1994 | 23709 | 0.010 |
Why?
|
| Research Design | 1 | 2014 | 6180 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2010 | 4496 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2006 | 2029 | 0.010 |
Why?
|
| Vincristine | 2 | 1991 | 1038 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2004 | 4626 | 0.010 |
Why?
|
| Protein Binding | 1 | 2008 | 9335 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 8950 | 0.010 |
Why?
|
| Platelet Count | 1 | 1997 | 777 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 8556 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 12444 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1997 | 675 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2006 | 3865 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 1995 | 376 | 0.010 |
Why?
|
| Stomatitis | 1 | 1995 | 271 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 1995 | 426 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 6130 | 0.010 |
Why?
|
| Procarbazine | 1 | 1991 | 172 | 0.010 |
Why?
|
| Lomustine | 1 | 1991 | 60 | 0.010 |
Why?
|
| Tuberculosis, Endocrine | 1 | 1990 | 1 | 0.010 |
Why?
|
| Fiber Optic Technology | 1 | 1993 | 289 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1993 | 1628 | 0.010 |
Why?
|
| Sputum | 1 | 1993 | 503 | 0.010 |
Why?
|
| Etoposide | 1 | 1991 | 630 | 0.010 |
Why?
|
| Adrenal Gland Diseases | 1 | 1990 | 141 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2010 | 26179 | 0.010 |
Why?
|
| Salmonella enteritidis | 1 | 1989 | 16 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 1993 | 442 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1995 | 2569 | 0.000 |
Why?
|
| Injections, Intravenous | 1 | 1990 | 1385 | 0.000 |
Why?
|
| Infant | 1 | 2010 | 36053 | 0.000 |
Why?
|
| Dactinomycin | 1 | 1988 | 304 | 0.000 |
Why?
|
| Drug Resistance | 1 | 1993 | 1617 | 0.000 |
Why?
|
| Up-Regulation | 1 | 1996 | 4122 | 0.000 |
Why?
|
| Teratoma | 1 | 1990 | 403 | 0.000 |
Why?
|
| Child, Preschool | 1 | 2010 | 42056 | 0.000 |
Why?
|
| Bronchoscopy | 1 | 1993 | 911 | 0.000 |
Why?
|
| Diagnosis, Differential | 2 | 1993 | 12968 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 2004 | 11481 | 0.000 |
Why?
|
| Chi-Square Distribution | 1 | 1993 | 3465 | 0.000 |
Why?
|
| Sensitivity and Specificity | 1 | 1993 | 14661 | 0.000 |
Why?
|
| Lung | 1 | 1993 | 9994 | 0.000 |
Why?
|